CClinicalTrials.gg
WithdrawnNCT02532153Updated Mar 3, 2017

The Impact of Ketamine on the Reward Circuitry of Suicidal Patients

A Phase 3 interventional study of Ketamine Hydrochloride in Suicidal Ideation and Suicide, sponsored by Massachusetts General Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-03.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Diagnostic

Why this study was withdrawn
No funding.
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Every 40 seconds, someone in the world dies by suicide. There is a lack of effective and safe antisuicidal agents for preventing suicide attempts. This leads to the immense worldwide individual, financial, and societal burden of suicide-which is projected to rise in the coming decades-supporting the need for antisuicidal treatments.

This treatment gap may be filled through understanding the neurobiology of suicide, which can guide the development of targeted antisuicidal treatments. Though some research has examined the neurobiology of suicidal ideation in the context of depression-implicating the orbital frontal cortex, anterior cingulate cortex, and striatum-the underlying pathophysiology and neurobiology of suicidal ideation as a separate construct from depression remains largely unknown. Therefore, the investigators propose to study the neurocircuitry of suicidal thoughts, regardless of whether or not depression is present.

02

Conditions studied

  • Suicidal Ideation
  • Suicide

Keywords

  • Suicidal Ideation
  • Suicide
  • Suicidal Thoughts
  • Depression
  • Ketamine
03

In context

Suicide

701 studies on the registry are indexed under Suicide; 183 are open to participants now.

Browse Suicide studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patients will:

  1. be ≥18 years old,
  2. read, understand, and provide written informed consent,
  3. have suicidal ideation for ≥ 2 months, per the Columbia Suicide Severity Rating Scale (C-SSRS),
  4. be on a stable psychiatric medication regimen for ≥28 days,
  5. maintain a treating doctor who is in agreement with study participation, and aware of the safety plan in the protocol,
  6. have a reliable chaperone accompany them home following the completion of the ketamine infusion day,
  7. be generally healthy, as assessed by medical history, physical examination (including vital signs), clinical laboratory evaluations, and electrocardiogram (EKG),
  8. be of non-childbearing potential or use of an acceptable form of birth control (females only), and
  9. be right handed.

Healthy Controls will:

  1. be ≥18 years old,
  2. read, understand, and provide written informed consent,
  3. have a negative pregnancy test on the morning of the MRI (females only).
  4. be right handed.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if any of the following criteria are met:

  1. delirium or dementia diagnosis,
  2. unstable medical illness or clinically significant laboratory results,
  3. history of clinically significant cardiovascular disease or electrocardiogram (EKG) findings, or medical conditions that put the patient at risk for possible cardiac side effects or alter brain morphology (e.g., diabetes, hypertension, traumatic brain injury), even if well controlled on medications,
  4. history of multiple adverse drug reactions,
  5. active substance use disorders (except nicotine and caffeine) within the past six months, positive urine toxicology screen, or past history of ketamine/PCP abuse,
  6. requirement of excluded medications that may interact with ketamine (e.g., narcotics, barbiturates, sedatives, theophylline, or St. John's Wort),
  7. BMI >35,
  8. pregnancy, breastfeeding, or unacceptable means of birth control (females only)
  9. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips)),
  10. concurrent participation in other research studies.

Healthy controls will be excluded if any of the following criteria are met:

  1. current or past Axis I diagnosis, including alcohol or substance abuse or dependence diagnosis (except for nicotine or caffeine) and suicidal thoughts/attempts,
  2. presence of MRI contraindications (e.g., presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips)),
  3. presence of medical illness likely to alter brain morphology and/or physiology (e.g., diabetes) even if controlled by medications,
  4. requirement of excluded medications that may interact with ketamine (e.g., narcotics, barbiturates, benzodiazepines, sedatives, theophylline, or St. John's Wort),
  5. presence of psychiatric disorders in first-degree relatives,
  6. pregnancy, breastfeeding, or unacceptable means of birth control (females only), or
  7. BMI >35.
05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Open-Label Ketamine

    Drug: Ketamine Hydrochloride

Interventions

  • DrugKetamine Hydrochloride

    Single open-label infusions

06

What researchers measure

Primary outcomes

  1. Columbia Suicide Severity Rating Scale (C-SSRS)

    Suicide Rating Scale from 1-5; higher numbers indicate increased suicidal thinking

    Time frame: 2 weeks

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 3, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02532153
Lead sponsor
Massachusetts General Hospital
Responsible party
Dawn F Ionescu (Assistant in Psychiatry, Massachusetts General Hospital) — Principal investigator
First posted
Aug 25, 2015
Start date
Feb 2017 (estimated)
Primary completion
Feb 2017 (estimated)
Completion
Feb 28, 2017
Last update
Mar 3, 2017

Study contacts

Dawn Ionescu, M.D.
principal investigator · MGH

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion